Citius Oncology Gets Nasdaq Extension to Meet $1 Bid Price Requirement
Citius Oncology (CTOR) received a Nasdaq extension until April 19, 2027, to meet the $1 minimum bid price requirement. The company must close at or above $1 for 10 consecutive days to avoid potential delisting. The extension does not impact its current listing on the Nasdaq Capital Market.
How this was made
The 30-second read
Why it matters
The extension gives Citius Oncology time to improve its share price, but the lingering compliance risk may keep investors cautious.
Market read
A micro‑cap biotech faces delisting risk; traders may monitor price movements for signs of compliance or further risk.
What to watch
Potential upcoming financing or partnership announcements that could lift the share price above the $1 threshold.
Background
Nasdaq requires listed stocks to maintain a minimum bid price of $1.00 for 10 consecutive business days. Failure leads to delisting procedures.
Ticker impact
Citius Oncology received a Nasdaq compliance extension to avoid delisting, requiring the stock to stay above $1.00 by April 19, 2027.
likely downward pressure as investors price in delisting risk
The company must maintain a $1.00 price for 10 consecutive days; any failure may lead to a delisting notice, which typically depresses the share price.
Market effects
Minimal; primarily affects micro‑cap biotech compliance considerations.
None
None
Counterpoint
If the company successfully regains compliance, the stock could rebound, making the risk overblown.
Key entities
- CompanyCitius Oncology
Biotech firm listed on Nasdaq under ticker CTOR.
- Regulatory BodyNasdaq
Exchange enforcing the $1.00 minimum bid price rule.
